tegsedi
Generic: INOTERSEN SODIUM
tegsedi: developed by 2 companies · 1 FDA decision.
tegsedi evidence translation
What we can confirm
1 FDA record
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about tegsedi, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
treatment of patients with polyneuropathy of hereditary transthyretin-mediated amyloidosisStage 1 or stage 2 polyneuropathy in hereditary transthyretin amyloidosis (hATTR)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| AKCEA THERAPEUTICS, INC. (AKCA) treatment of patients with polyneuropathy of hereditary tran… | Approved |
| PTC THERAPEUTICS, INC. (PTCT) Stage 1 or stage 2 polyneuropathy in hereditary transthyreti… | Approved |
FDA Decisions1 records
Frequently asked questions
Who is developing tegsedi?
tegsedi is being developed by AKCEA THERAPEUTICS, INC., PTC THERAPEUTICS, INC..
What is tegsedi's latest FDA decision?
The most recent tracked FDA decision for tegsedi is Approval, dated October 5, 2018.